Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Wilson Therapeutics in connection with directed share issue
Mandate

Vinge advises Wilson Therapeutics in connection with directed share issue

December 12, 2017

Vinge has advised Wilson Therapeutics on a directed new issue of shares, whereby Wilson Therapeutics raises proceeds of approximately SEK 244 million, before issue costs.

The share issue is directed to a number of selected institutions and sector specialist funds, internationally and in Sweden, on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Christian Lindhé, Erik Sjöman, Mattias Sköld, Ludvig Frithiof and Astrid Karlsson.

Related

Vinge advises FAM AB on the acquisition of Aktiebolaget Näckström

 Vinge has advised FAM AB on its acquisition of Aktiebolaget Näckström from Vectura Fastigheter AB. The principal assets of Aktiebolaget Näckström comprise the property Stockholm Näckström 6 (Arsenalsgatan 8) and Villa Täcka udden.
October 16, 2025

Vinge has advised FAM in connection with its investment in GreenIron

 Vinge has advised FAM AB, owned by the Wallenberg Foundations, in connection with its investment in GreenIron H2 AB. Through the round, GreenIron raised in total SEK 125 million in additional funding from existing shareholders, with FAM now becoming the company’s largest owner.
October 16, 2025

Vinge has advised on the sale of Westcomp AB to Tången Industrikapital AB

 Pursuant to the transaction, Tången acquires approximately 91 per cent of the shares in Westcomp.
October 15, 2025